Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.57 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.57 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CDK9 | P50750 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077995 | 1.00 | CD274 (0.57) | CD274VSIRPDCD1LG2PDCD1PIK3CG | |
| SCHEMBL18077940 | 0.89 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL19866981 | 0.89 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL18077963 | 0.89 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19867028 | 0.89 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL19867082 | 0.88 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL19867020 | 0.88 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL18077976 | 0.88 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL18077927 | 0.88 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1KDM4E | |
| SCHEMBL19867038 | 0.84 | CD274 (0.58) | CD274VSIRPDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | CD274 2/4885VSIR 2158/4885PDCD1LG2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.